Allotrope Bio

Treats donor organs before transplantation so the recipient needs less lifelong immunosuppression.

Allotrope Bio developed an ex-vivo gene therapy that quietens the immune signals of a donor organ before it is transplanted. After the programme the company closed a $4.1M pre-Series A to take its lead candidate towards first-in-human studies in lung transplantation.